Micro-power magnetic bio-membrane reactor von TAN TINGYUN, TAN SHOUYUN, PAN MEI, HAN XIANGYUN, WU BANGYAN, LING YAOLIN, YAO JIANCHUN

Volltext bestellen

Unsupervised Sub-Pixel Water Body Mapping with Sentinel-3 OLCI Image von Wang, Xia, Ling, Feng, Yao, Huaiying, Liu, Yaolin, Xu, Shuna

Volltext

Spatio-Temporal Change Detection of Ningbo Coastline Using Landsat Time-Series Images during 1976–2015 von Wang, Xia, Liu, Yaolin, Ling, Feng, Liu, Yanfang, Fang, Feiguo

Volltext

Analysis of Coastline Extraction from Landsat-8 OLI Imagery von Liu, Yaolin, Wang, Xia, Ling, Feng, Xu, Shuna, Wang, Chengcheng

Volltext

D‐1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity von Shi, Zhe, Weng, Jifang, Niu, Haotao, Yang, Hong, Liu, Rongfeng, Weng, Yan, Zhu, Qingqing, Zhang, Yihong, Tao, Liangshan, Wang, Zhenwu, Huh, Seok Jae, Jiang, Yueheng, Mei, Hong, Dai, Xing, Zhang, Ling, Wang, Yaolin

Volltext

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer von Jian, Hong, Wang, Kai, Cheng, Ying, Ding, Lieming, Wang, Yang, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Lu, Shun

Volltext

Activation of autophagy contributes to the renoprotective effect of postconditioning on acute kidney injury and renal fibrosis von Song, Yaolin, Tao, Qianyu, Yu, Lixia, Li, Ling, Bai, Tingting, Song, Xiaoxiao, Hu, Haiqi, Li, Yulin, Tan, Xiaohua

Volltext

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results von Li, Ziming, Song, Zhengbo, Zhao, Yanqiu, Wang, Pingli, Jiang, Liyan, Gong, Yi, Zhou, Jianying, Jian, Hong, Dong, Xiaorong, Zhuang, Wu, Cang, Shundong, Yang, Nong, Fang, Jian, Shi, Jianhua, Lu, Junguo, Ma, Rui, Wu, Ping, Zhang, Yingqian, Song, Mengmeng, Xu, Chun-Wei, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Wang, Xicheng, Zhang, Yiping, Lu, Shun

Volltext

Abstract 1056: Potent in vivo anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor m... von Shi, Zhe, Weng, Jifang, Fan, Xiaochong, Zhu, Qingqing, Robb, Emily, Moriarty, Alyssa, Wick, Michael, Jiang, Yueheng, Zhang, Ling, Dai, Xing, Wang, Yaolin

Volltext

Abstract 932: Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models von Shi, Zhe, Weng, Jifang, Fan, Xiaochong, Wang, Emma, Zhu, Qingqing, Tao, Liangshan, Han, Zixing, Wang, Zhenwu, Niu, Haotao, Jiang, Yueheng, Zhang, Ling, Dai, Xing, Wang, Yaolin

Volltext

D-1553: A novel KRAS G12C inhibitor with potent and selective cellular and in vivo antitumor activity von Shi, Zhe, Weng, Jifang, Niu, Haotao, Yang, Hong, Liu, Rongfeng, Weng, Yan, Zhu, Qingqing, Zhang, Yihong, Tao, Liangshan, Wang, Zhenwu, Huh, Seok Jae, Jiang, Yueheng, Mei, Hong, Dai, Xing, Zhang, Ling, Wang, Yaolin

Volltext

Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study von Ruan, Dan-yun, Lee, Myung Ah, Deng, Yanhong, Lee, Keun-Wook, Millward, Michael, Grewal, Jaspreet Singh, Gadgeel, Shirish M., Sanborn, Rachel E., Hou, Xinfang, Wei, Shaozhong, Huh, Seok Jae, Liu, Fu-Rong, Xie, Xiaoxi, Xiang, Ziyong, Shi, Zhe, Wang, Yaolin, Zhang, Ling, Richardson, Gary Edward, Xu, Rui-Hua

Volltext

Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer von Osborne, Cynthia, Richards, Donald A, Wilks, Sharon T, Diab, Sami, Juric, Dejan, Lathrop, Kate, Silber, Andrea, Edenfield, William, Aulakh, Amardeep, Cho, Ben, Xu, Binghe, Sun, Tao, Ouyang, Quchang, Shi, Yanxia, Stazzone, Kathryn, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Hamilton, Erika P

Volltext

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody von Wang, Yan, Hailey, Judith, Williams, Denise, Wang, Yaolin, Lipari, Philip, Malkowski, Michael, Wang, Xiaoying, Xie, Lei, Li, Guanghua, Saha, Deba, Ling, Wai Lam W, Cannon-Carlson, Susan, Greenberg, Robert, Ramos, Robert A, Shields, Robert, Presta, Leonard, Brams, Peter, Bishop, W Robert, Pachter, Jonathan A

Volltext

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial von Li, Ziming, Dang, Xiaomin, Huang, Dingzhi, Jin, Shi, Li, Weiwei, Shi, Jianhua, Wang, Xicheng, Zhang, Yiping, Song, Zhengbo, Zhang, Junping, Zhuang, Wu, Liu, Xuewen, Jiang, Liyan, Meng, Xiangjiao, Zhao, Mingfang, Zhou, Jianying, Zhang, Liangming, Wang, Pingli, Luo, Hui, Yang, Junquan, Cang, Shundong, Wang, Xiang, Zhang, Ling, Lu, Shun, Li, Ziming, Dang, Xiaomin, Huang, Dingzhi, Jin, Shi, Li, Weiwei, Shi, Jianhua, Wang, Xicheng, Zhang, Yiping, Song, Zhengbo, Zhang, Junping, Zhuang, Wu, Liu, Xuewen, Jiang, Liyan, Meng, Xiangjiao, Zhao, Mingfang, Zhou, Jianying, Zhang, Liangming, Wang, Pingli, Luo, Hui, Yang, Junquan, Cang, Shundong, Wang, Xiang, Wang, Jing, Cui, Jiuwei, Yu, Yan, Zhang, Zhihong, Lu, Junguo, Yang, Weihua, Li, Gaofeng, Feng, Jifeng, Lv, Dongqing, Wu, Lin, Fang, Yong, Wang, Yan, Zhao, Yanqiu, Cao, Baoshan, Zhu, Wei, Zhuang, Zhixiang, Li, Qingshan, Wang, Mingxi, Zhou, Huan, Dong, Xiaorong, Hu, Sheng, Fang, Jian, Xu, Chun-Wei, Zhang, Yihong, Wang, Wenjia, Xiang, Ziyong, Shi, Zhe, Wang, Yaolin, Zhang, Ling, Lu, Shun

Volltext

Abstract CT505: Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation von Jian, Hong, Song, Zhenbo, Zhang, Yiping, Li, Kunyan, Yang, Nong, Moore, Melissa, Wang, Pingli, Zhao, Yanqiu, Gong, Yi, Underhill, Craig, Kim, Sang-We, Yang, Cheng-Ta, Xiang, Ziyong, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Lu, Shun

Volltext

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results von Li, Ziming, Song, Zhengbo, Zhao, Yanqiu, Wang, Pingli, Jiang, Liyan, Gong, Yi, Zhou, Jianying, Jian, Hong, Dong, Xiaorong, Zhuang, Wu, Cang, Shundong, Yang, Nong, Fang, Jian, Shi, Jianhua, Lu, Junguo, Ma, Rui, Wu, Ping, Zhang, Yingqian, Song, Mengmeng, Xu, Chun-Wei, Shi, Zhe, Zhang, Ling, Wang, Yaolin, Wang, Xicheng, Zhang, Yiping, Lu, Shun

Volltext

Garsorasib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial von Li, Ziming, Dang, Xiaomin, Huang, Dingzhi, Jin, Shi, Li, Weiwei, Shi, Jianhua, Wang, Xicheng, Zhang, Yiping, Song, Zhengbo, Zhang, Junping, Zhuang, Wu, Liu, Xuewen, Jiang, Liyan, Meng, Xiangjiao, Zhao, Mingfang, Zhou, Jianying, Zhang, Liangming, Wang, Pingli, Luo, Hui, Yang, Junquan, Cang, Shundong, Wang, Xiang, Zhang, Ling, Lu, Shun

Volltext

Studying the viscosity of lower crust of Qinghai-Tibet Plateau according to post-seismic deformation von Zhang, ChaoJun, Cao, JianLing, Shi, YaoLin

Volltext

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or me... von Price, Timothy, Grewal, Jaspreet, Abed, Afaf, Moore, Melissa, Yeh, Yu-Min, Gadgeel, Shirish, Richardson, Gary, Underhill, Craig, Ganju, Vinod, Lee, Keun-Wook, Huh, Seok Jae, Kim, Sang-We, Yang, Chih-Hsin, Chen, Yuh-Min, Xiang, Ziyong, Shi, Zhe, Wang, Yaolin, Zhang, Ling, Millward, Michael

Volltext